In the present study, we divided patients into three subgroups according to the timing and purpose of serum KL-6 testing to verify the significance of serum KL-6 in the diagnosis and severity assessment of ILD at its onset (categories 1 and 2) and in predicting the occurrence of ILD before lung cancer treatment at baseline (category 3). Here, MUC1 is linked to lung cancer.